Global Intravenous Immunoglobulin (IVIG) Market Insights on Future Opportunities and Geographical Landscape during Forecast 2017-2024

Published on : May 31, 2018

Albany, New York, May 31, 2018: A freshly compiled business intelligence study has been broadcasted to the vast database of Market Research Hub (MRH), which is titled as “Intravenous Immunoglobulin (IVIG) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2024”. The study which provides wide-ranging insights into the market current scenario and future growth prospects during the mentioned forecast period of 2017-2025. For accurate results, the global market growth has been analyzed in terms of revenue and volume estimates (in US$ Mn and Thousand Units), across different geographies such as North America, Europe, Asia-Pacific, Middle East and Africa and Latin America.

Firstly, the analysts have presented an in-depth introduction of Intravenous Immunoglobulin and data analysis of the global market with respect to the segments based on the indication, and end-user. In the recent past, IVIG has proven their worth in treating autoimmune diseases such as multiple sclerosis, primary humoral immunodeficiency (PIDD), autoimmune haemolytic anemia, immune thrombocytopenia purpura (ITP), and Kawasaki syndrome.

Key Findings from the Report

  • In the present time, rising prevalence of a variety of hematological and neurological disorders is the chief factor driving the intravenous immunoglobulin (IVIG) market. As per the research findings, the market has been projected to expand at a remarkable CAGR of 8.5% from 2017 to 2024. Also, the analyst of the report has identified that the intravenous immunoglobulin market will have opportunities worth US$14,923.2 million by 2024 across the globe, which is noticeably higher than the market’s calculated valuation of US$8,419.7 million as of 2017.
  • Further, the research also adds that intravenous immunoglobulin market is anticipated to gain traction from factors such as an increase in elderly population, increasing usage of off-label indications, advancements in the production technologies and purification methods, encouraging government initiatives, and improvements in healthcare infrastructure across emerging markets.
  • For a better understanding, the major segments identified in the study include disease indication which highlights CIDP and primary humoral immunodeficiency are the two segments that organized for more than half of the total demand in this market. End-user include Hospitals, Clinics and Home Care. Of these, the hospitals segment is currently leading.
  • In terms of geography, the report finds that North America is a major market for intravenous immunoglobulin due to the availability of wide range of products, advancements in technology, and increasing number of patients with blood & neurological disorders.

At last, the competitive landscape section has been included in which key players are profiled on the basis of important attributes, such as financial overview, business strategies, and recent developments. Grifols S.A., Baxalta Incorporated, CSL Behring LLC, Biotest AG, China Biologic Products, Inc., Octapharma AG Kedrion S.p.A., LFB Biomedicaments S.A., and Sanquin Plasma Products B.V. are the major players profiled in the study.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top